Perrigo Company Intrinsic Stock Value – PERRIGO COMPANY Reports Total Revenue of USD 1193.1 Million and Net Income of USD 8.4 Million for Q2 2023
August 16, 2023
🌥️Earnings Overview
On August 8 2023, PERRIGO COMPANY ($NYSE:PRGO) reported total revenue of USD 1193.1 million and net income of USD 8.4 million for the second quarter ending June 30 2023. This marked a 6.4% and 112.9% increase year-over-year respectively.
Stock Price
On Tuesday, PERRIGO COMPANY stock opened at $38.1 and closed at $39.9, marking a 8.5% rise from the prior closing price of 36.8. The increase in the share price was attributed to the company’s strong financial performance in Q2 2023. Moreover, it was noted that PERRIGO COMPANY was well-positioned to ride out any further market volatility in the coming quarters.
The positive results reported by PERRIGO COMPANY is indicative of the company’s strength and resilience even amidst uncertain economic conditions. Moving forward, the company is confident that its focus on innovation and efficiency will continue to drive growth and profitability in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Perrigo Company. More…
| Total Revenues | Net Income | Net Margin |
| 4.63k | -67.6 | -0.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Perrigo Company. More…
| Operations | Investing | Financing |
| 317.4 | -70.9 | -184.8 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Perrigo Company. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.96k | 6.12k | 35.81 |
Key Ratios Snapshot
Some of the financial key ratios for Perrigo Company are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -3.0% | -23.6% | 3.9% |
| FCF Margin | ROE | ROA |
| 4.9% | 2.3% | 1.0% |
Analysis – Perrigo Company Intrinsic Stock Value
GoodWhale has analyzed PERRIGO COMPANY‘s financials and has determined that the intrinsic value of its shares is around $53.8, as calculated by our proprietary Valuation Line. Currently, PERRIGO COMPANY stock is traded at $39.9, which means it is undervalued by 25.9%. This presents a great opportunity for investors who are looking to capitalize on the potential upside of the stock. More…
Peers
Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.
– Yuhan Corp ($KOSE:000105)
Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.
– JW Pharmaceutical ($KOSE:001060)
As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.
Summary
Perrigo Company reported strong financial results for the second quarter of 2023, with total revenue and net income increasing 6.4% and 112.9% year-over-year, respectively. This upbeat performance sent share prices higher on the day of the announcement. Investors have cause to be optimistic about Perrigo Company, as its second-quarter numbers suggest significant growth and profitability. With strong financials, and a positive outlook for the future, investors may find that now is the perfect time to look into investing in this company.
